Quick Answer
4D Molecular Therapeutics, Inc. reported Stockholders Equity of $505.66 million for the year ending 2025.
- 4D Molecular Therapeutics, Inc. showed a decrease of -1.0% in Stockholders Equity from 2024 to 2025.
- This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$85.04 million | Q2 2020: -$99.16 million | Q3 2020: -$105.29 million | Q1 2021: $242.43 million | Q2 2021: $240.65 million | Q3 2021: $224.13 million | Q1 2022: $296.06 million | Q2 2022: $272.52 million | Q3 2022: $251.44 million | Q1 2023: $218.61 million | Q2 2023: $325.14 million | Q3 2023: $329.93 million | Q1 2024: $600.56 million | Q2 2024: $588.34 million | Q3 2024: $552.95 million | Q1 2025: $469.72 million | Q2 2025: $420.89 million | Q3 2025: $368.98 million.
- Over the full 8 years of available data (2018 to 2025), 4D Molecular Therapeutics, Inc.'s Stockholders Equity has grown by 1,933.0%.
- Historical annual values: Fiscal year 2025: $505.66 million | Fiscal year 2024: $510.61 million | Fiscal year 2023: $307.83 million | Fiscal year 2022: $231.34 million | Fiscal year 2021: $319.11 million | Fiscal year 2020: $256.39 million | Fiscal year 2019: -$72.97 million | Fiscal year 2018: -$27.59 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: